肝细胞癌：流行病学、筛查和肝储备功能评估。
Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve.
机构信息
Division of Hepatology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A.
出版信息
Curr Oncol. 2020 Nov;27(Suppl 3):S138-S143. doi: 10.3747/co.27.7181. Epub 2020 Nov 1.
Abstract
Hepatocellular carcinoma is a leading cause of cancer-related mortality worldwide. This review summarizes the epidemiology and causes of the disease, and the roles of screening and surveillance for early tumour detection. It also highlights the important role of assessment of hepatic reserve in consideration of appropriate staging and treatment.
摘要
肝细胞癌是全球癌症相关死亡的主要原因。本文综述了该病的流行病学和病因，以及筛查和监测在早期肿瘤检测中的作用。本文还强调了评估肝脏储备在适当分期和治疗中的重要作用。
相似文献
1
Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve.肝细胞癌：流行病学、筛查和肝储备功能评估。
Curr Oncol. 2020 Nov;27(Suppl 3):S138-S143. doi: 10.3747/co.27.7181. Epub 2020 Nov 1.
2
Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment.肝细胞癌：流行病学、筛查、影像诊断、疗效评估及治疗综述
Curr Probl Diagn Radiol. 2015 Nov-Dec;44(6):479-86. doi: 10.1067/j.cpradiol.2015.04.004. Epub 2015 Apr 16.
3
Screening and surveillance for hepatocellular carcinoma: perspective of a new era?肝细胞癌的筛查与监测：新时代的视角？
Expert Rev Anticancer Ther. 2016 Dec;16(12):1291-1302. doi: 10.1080/14737140.2016.1246965. Epub 2016 Oct 24.
4
Hepatocellular carcinoma: diagnostics and screening.肝细胞癌：诊断和筛查。
J Eval Clin Pract. 2012 Apr;18(2):335-42. doi: 10.1111/j.1365-2753.2010.01599.x. Epub 2010 Nov 30.
5
Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis.肝细胞癌：流行病学、监测和诊断。
Semin Liver Dis. 2010 Feb;30(1):3-16. doi: 10.1055/s-0030-1247128. Epub 2010 Feb 19.
6
Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk?肝癌的流行病学变化：如何进行筛查和识别高危患者？
Dig Dis Sci. 2019 Apr;64(4):903-909. doi: 10.1007/s10620-019-05515-8.
7
Hepatocellular carcinoma.肝细胞癌
Curr Opin Gastroenterol. 2006 May;22(3):248-53. doi: 10.1097/01.mog.0000218961.86182.8c.
8
Hepatocellular cancer.肝细胞癌
West Indian Med J. 2009 Jun;58(3):273-6.
9
The diagnosis and treatment of hepatocellular carcinoma.肝细胞癌的诊断与治疗
Semin Diagn Pathol. 2017 Mar;34(2):153-159. doi: 10.1053/j.semdp.2016.12.011. Epub 2016 Dec 20.
10
Surveillance for hepatocellular carcinoma...a hotly debated issue.肝细胞癌的监测……一个备受争议的问题。
Acta Gastroenterol Belg. 2004 Jul-Sep;67(3):255-64.
引用本文的文献
1
Analysis of the optimal patterns of serum alpha fetoprotein (AFP), AFP-L3% and protein induced by vitamin K absence or antagonist-II (PIVKA-II) detection in the diagnosis of liver cancers.血清甲胎蛋白（AFP）、甲胎蛋白异质体-L3%（AFP-L3%）及维生素K缺乏或拮抗剂-II诱导蛋白（PIVKA-II）检测在肝癌诊断中的最佳模式分析
PeerJ. 2025 Jul 21;13:e19712. doi: 10.7717/peerj.19712. eCollection 2025.
2
Diagnostic performance of contrast-enhanced ultrasonography for predicting therapeutic response to radiofrequency ablation in patients with hepatocellular carcinoma: a meta-analysis.超声造影预测肝细胞癌患者射频消融治疗反应的诊断性能：一项荟萃分析。
Discov Oncol. 2025 Jul 1;16(1):1237. doi: 10.1007/s12672-025-03008-x.
3
Hepatocellular Carcinoma: The Search for an Optimal Screening Test.肝细胞癌：寻找最佳筛查检测方法
Middle East J Dig Dis. 2025 Jan;17(1):31-39. doi: 10.34172/mejdd.2025.407. Epub 2025 Jan 31.
4
Risk of malignancy in adult patients with congenital heart disease: a clinical practice review.成人先天性心脏病患者的恶性肿瘤风险：一项临床实践综述
Cardiovasc Diagn Ther. 2025 Feb 28;15(1):195-206. doi: 10.21037/cdt-24-388. Epub 2025 Feb 25.
5
Liquid biopsy kinetics and detection of ERBB2 amplification/HER2-positivity in refractory hepatocellular carcinoma.液体活检动力学与难治性肝细胞癌中ERBB2扩增/HER2阳性的检测
J Liq Biopsy. 2023 Sep 26;2:100009. doi: 10.1016/j.jlb.2023.100009. eCollection 2023 Dec.
6
Decoding the Prognostic Significance and Therapeutic Implications of Inflammation-Based Scores in Hepatocellular Carcinoma: A Comprehensive Review.解读基于炎症的评分在肝细胞癌中的预后意义及治疗价值：一项综述
Cancers (Basel). 2024 Jul 15;16(14):2549. doi: 10.3390/cancers16142549.
7
Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma.晚期不可切除肝细胞癌的真实世界治疗模式、临床结局及医疗资源利用情况
Can Liver J. 2022 Nov 7;5(4):476-492. doi: 10.3138/canlivj-2022-0001. eCollection 2022 Nov.
8
Twelve protections evolved for the brain, and their roles in extending its functional life.大脑进化出了十二种保护机制，以及它们在延长大脑功能寿命方面的作用。
Front Neuroanat. 2023 Nov 6;17:1280275. doi: 10.3389/fnana.2023.1280275. eCollection 2023.
9
circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis.circSLCO1B7 通过 miR-556-3p/DAB2IP 轴抑制肝细胞癌的恶性进展。
Aging (Albany NY). 2023 Nov 24;15(22):13329-13344. doi: 10.18632/aging.205244.
10
Prediction of survival and analysis of prognostic factors for hepatocellular carcinoma: a 20-year of imaging diagnosis in Upper Northern Thailand.预测生存并分析肝癌的预后因素：泰国上北部 20 年的影像学诊断。
BMC Cancer. 2023 Nov 4;23(1):1063. doi: 10.1186/s12885-023-11429-6.
本文引用的文献
1
Human Virus Transcriptional Regulators.人类病毒转录调控因子
Cell. 2020 Jul 9;182(1):24-37. doi: 10.1016/j.cell.2020.06.023.
2
Epidemiology of Hepatocellular Carcinoma.肝细胞癌的流行病学
Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288. Epub 2020 Nov 24.
3
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.非酒精性脂肪性肝病且肝酶正常患者发生肝硬化和肝细胞癌的风险。
Hepatology. 2020 Oct;72(4):1242-1252. doi: 10.1002/hep.31157.
4
Epidemiology and surveillance for hepatocellular carcinoma: New trends.肝癌的流行病学和监测：新趋势。
J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025.
5
International trends in hepatocellular carcinoma incidence, 1978-2012.国际 1978-2012 年肝细胞癌发病率趋势。
Int J Cancer. 2020 Jul 15;147(2):317-330. doi: 10.1002/ijc.32723. Epub 2019 Nov 5.
6
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌：趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
7
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?丙型肝炎病毒时代的肝细胞癌：我们是否应该改变范式？
World J Gastroenterol. 2019 Aug 7;25(29):3929-3940. doi: 10.3748/wjg.v25.i29.3929.
8
Correlation between rs738409 polymorphism and hepatocellular carcinoma: a meta-analysis of 10,330 subjects.rs738409 多态性与肝细胞癌的相关性：一项包含 10330 例个体的荟萃分析。
Int J Biol Markers. 2019 Jun;34(2):117-122. doi: 10.1177/1724600818812471. Epub 2019 Mar 11.
9
Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis.PNPLA3基因rs738409多态性与非酒精性脂肪性肝病（NAFLD）易感性及严重程度的关联：一项荟萃分析。
Medicine (Baltimore). 2019 Feb;98(7):e14324. doi: 10.1097/MD.0000000000014324.
10
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
Zotero 插件